Secular trend analysis of antibiotic utilisation in China's hospitals 2011-2018, a retrospective analysis of procurement data.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
15 04 2020
Historique:
received: 01 11 2019
accepted: 24 03 2020
entrez: 17 4 2020
pubmed: 17 4 2020
medline: 19 5 2021
Statut: epublish

Résumé

This study was aimed to explore the secular trends of antibiotic utilisation in China's hospitals over an 8-year period. We retrospectively analysed aggregated monthly antibiotic procurement data of 586 hospitals from 28 provinces in China from January 2011 to December 2018. Information including generic name, procurement amount, dosage form, strength, the route of administration, and geographical data were collected. Population weighted antibiotic utilisation were expressed in DDD per 1000 inhabitants per day (DID). WHO's 'Access, Watch, Reserve' categorization was also adopted to analyse antibiotic utilisation. Between 2011 and 2018, total antibiotic utlisation in China's hospitals increased by 39.6% (from 4.8 DID in 2010 to 6.7 DID in 2018). Antibiotic utilisation was stable or had moderately decreased in 13 provinces, while in the other 15 provinces they had substantially increased. Cephalosporins were the most consumed antibiotics, accounting for 26.9% of the total antibiotic utilisation (1.8 DID/6.7 DID). In 2018, antibiotics in the Access category comprised 19.4% of the total utilisation (1.3 DID/6.7 DID), where antibiotics in the Watch category comprised the largest proportion of 71.6% (4.8 DID/6.7 DID). Population-weighted antibiotic utlisation was greater in secondary hospitals than in tertiary hospitals (7.3 DID vs 6.6 DID). The utilisation of oral forms was almost two times the amount of parenteral forms in secondary hospitals, whereas in tertiary hospitals the amounts were about the same. Despite efforts have been made towards restricting antibiotic use by the Chinese government, antibiotic utilisation demonstrated an upward trend after the medical reform. The increase of last-resort antibiotics raises serious concern for public health. Current patterns of antibiotic utilisation demonstrated that gaps are existed towards the global target set up by the WHO. To better facilitate proper antibiotic use, more efforts are needed to explore the appropriateness of antibiotic use at the individual level.

Sections du résumé

BACKGROUND
This study was aimed to explore the secular trends of antibiotic utilisation in China's hospitals over an 8-year period.
METHODS
We retrospectively analysed aggregated monthly antibiotic procurement data of 586 hospitals from 28 provinces in China from January 2011 to December 2018. Information including generic name, procurement amount, dosage form, strength, the route of administration, and geographical data were collected. Population weighted antibiotic utilisation were expressed in DDD per 1000 inhabitants per day (DID). WHO's 'Access, Watch, Reserve' categorization was also adopted to analyse antibiotic utilisation.
RESULTS
Between 2011 and 2018, total antibiotic utlisation in China's hospitals increased by 39.6% (from 4.8 DID in 2010 to 6.7 DID in 2018). Antibiotic utilisation was stable or had moderately decreased in 13 provinces, while in the other 15 provinces they had substantially increased. Cephalosporins were the most consumed antibiotics, accounting for 26.9% of the total antibiotic utilisation (1.8 DID/6.7 DID). In 2018, antibiotics in the Access category comprised 19.4% of the total utilisation (1.3 DID/6.7 DID), where antibiotics in the Watch category comprised the largest proportion of 71.6% (4.8 DID/6.7 DID). Population-weighted antibiotic utlisation was greater in secondary hospitals than in tertiary hospitals (7.3 DID vs 6.6 DID). The utilisation of oral forms was almost two times the amount of parenteral forms in secondary hospitals, whereas in tertiary hospitals the amounts were about the same.
CONCLUSIONS
Despite efforts have been made towards restricting antibiotic use by the Chinese government, antibiotic utilisation demonstrated an upward trend after the medical reform. The increase of last-resort antibiotics raises serious concern for public health. Current patterns of antibiotic utilisation demonstrated that gaps are existed towards the global target set up by the WHO. To better facilitate proper antibiotic use, more efforts are needed to explore the appropriateness of antibiotic use at the individual level.

Identifiants

pubmed: 32295639
doi: 10.1186/s13756-020-00709-6
pii: 10.1186/s13756-020-00709-6
pmc: PMC7160954
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53

Subventions

Organisme : Medical Research Council
ID : MR/S013717/1
Pays : United Kingdom

Références

Lancet Infect Dis. 2014 Aug;14(8):742-750
pubmed: 25022435
BMC Public Health. 2013 Jan 16;13:41
pubmed: 23324386
Infect Control Hosp Epidemiol. 2018 May;39(5):584-589
pubmed: 29485018
Emerg Infect Dis. 2008 Nov;14(11):1722-30
pubmed: 18976555
PLoS One. 2017 Dec 27;12(12):e0190314
pubmed: 29281716
Lancet Infect Dis. 2013 Mar;13(3):189-91
pubmed: 23427881
J Antimicrob Chemother. 2019 Jun 1;74(6):1731-1740
pubmed: 30820565
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203488
BMJ. 2016 May 16;353:i2755
pubmed: 27184065
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
PLoS One. 2018 May 3;13(5):e0196668
pubmed: 29723230
J Antimicrob Chemother. 2018 Mar 1;73(3):814-820
pubmed: 29272452
Glob Health Action. 2017;10(1):1287334
pubmed: 28462635
J Antimicrob Chemother. 2017 Jan;72(1):273-280
pubmed: 27624571
Eur J Clin Microbiol Infect Dis. 2013 May;32(5):581-95
pubmed: 23268203
J Antimicrob Chemother. 2016 Jun;71(6):1723-9
pubmed: 26892776
Lancet Infect Dis. 2018 May;18(5):516-525
pubmed: 29452941
Biomed Res Int. 2018 Nov 1;2018:5968653
pubmed: 30519582
Soc Sci Med. 2019 Mar;224:149-155
pubmed: 30784853

Auteurs

Haishaerjiang Wushouer (H)

Center for Strategic Studies, Chinese Academy of Engineering, No.2 Bingjiaokou HuTong, Xicheng District, Beijing, 100088, China.
School of Medicine, Tsinghua University, No.30 Shuangqing Road, Haidian District, Beijing, 100084, China.
International Research Center for Medicinal Administration (IRCMA), Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China.

Yue Zhou (Y)

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China.

Xi Zhang (X)

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China.

Mengyuan Fu (M)

Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China.

Daiming Fan (D)

State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical University, No. 15 Changlexi Road, Xincheng District, Xi'an, 710032, China.

Luwen Shi (L)

International Research Center for Medicinal Administration (IRCMA), Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China. shilu@bjmu.edu.cn.
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China. shilu@bjmu.edu.cn.

Xiaodong Guan (X)

International Research Center for Medicinal Administration (IRCMA), Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China. guanxiaodong@pku.edu.cn.
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, No.38 Xueyuan Road, Haidian District, Beijing, 100191, China. guanxiaodong@pku.edu.cn.
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 133 Brookline Avenue, Boston, MA, 02215, USA. guanxiaodong@pku.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH